Pure Global
NCT02755428

Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases

Safety and Efficacy of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases
Chinese Academy of Sciences·Early Phase 1·ClinicalTrials.gov·biological
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Age-related Macular Degeneration
Drug/Device/Intervention
retinal pigment epithelium transplantation
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Chinese Academy of Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Early Phase 1
Start date
Jan 01, 2018
End date
Dec 01, 2020
Enrollment
10 participants
Primary outcome

safety and tolerance of transplantation

Summary

This project intends to transplant human embryonic stem cells derived retinal pigment
 epitheliums into subretinal space of patients to treat dry age-related macular
 degeneration(dry-AMD).And we will assess the safety and efficacy of RPE transplants to treat
 dry AMD.

ICD-10 classifications
Peripheral retinal degenerationCorneal degenerationHereditary retinal dystrophyOptic atrophy in diseases classified elsewhereDisorders of choroid and retina
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT02755428
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT02755428 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Chinese Academy of Sciences and is currently status unknown. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.